Clinical Trials Logo

Clinical Trial Summary

Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society. Unfortunately, 25-30% of schizophrenia patients respond poorly to antipsychotic medication. Moreover, psychotherapeutic treatment alternatives are very limited for this suffering population. This unmet clinical need requires innovation and action. Psychotherapeutic treatment alternatives such as Cognitive Behavior Therapy (CBT) provide at best moderate results. Using immersive virtual reality, we recently tested a novel psychotherapeutic intervention, Avatar Therapy (AT), where the therapist engages in a dialogue with the patient through a virtual representation of the patient's distressing voice. This approach, being both relational and experiential, provides a unique opportunity to aid patients gain control over their voice. The results of our pilot study on AT were clinically promising for the severity and distress related to hallucinations, positive symptomatology and emotion regulation. To further research in this field, the primary goal of this randomized-controlled, single-site parallel study is to show that AT is superior to CBT for the treatment of persistent auditory hallucinations in schizophrenia. Our secondary goal is to examine the effects of these interventions on emotion regulation, mood symptoms (anxiety and depression), self-esteem, level of functioning and quality of life.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03585127
Study type Interventional
Source Ciusss de L'Est de l'Île de Montréal
Contact
Status Completed
Phase N/A
Start date March 1, 2017
Completion date July 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT03076346 - Neural Biomarkers of Clozapine Response
Completed NCT03148639 - Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Recruiting NCT06270108 - The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia Early Phase 1
Not yet recruiting NCT06060886 - Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis Phase 4
Recruiting NCT05694000 - Hippocampus DBS in Treatment-resistant Schizophrenia N/A
Completed NCT01105481 - Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients Phase 4
Recruiting NCT02361554 - Deep Brain Stimulation in Treatment Resistant Schizophrenia N/A
Recruiting NCT05299749 - Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations N/A
Not yet recruiting NCT05259306 - Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia N/A
Terminated NCT03230864 - Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Phase 3
Recruiting NCT05337904 - Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia N/A
Terminated NCT03868839 - Telmisartan Pilot Study on Treatment Resistant Schizophrenia Phase 2
Not yet recruiting NCT04528095 - SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia Phase 3
Not yet recruiting NCT06128408 - The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset
Recruiting NCT05074732 - Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.
Completed NCT03983018 - Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019) Phase 1
Recruiting NCT05741502 - An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine Phase 4
Recruiting NCT04054778 - Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory Hallucinations N/A